Last updated: March 19, 2026
What is the scope of AU2019226227?
Patent AU2019226227 claims a novel pharmaceutical compound with specific structural features, targeting a certain disease indication. The patent's scope covers both the compound itself and its use in a specific method of treatment. It also encompasses pharmaceutical compositions containing the compound.
Key features of the scope include:
- Compound Class: The patent describes a class of compounds characterized by a core structure with substitutions at defined positions.
- Uses: The patent claims methods of treating diseases associated with the target pathway, particularly focusing on indications such as inflammatory disorders or cancer.
- Formulations: Specific formulations that include the compound are covered, including oral, injectable, or topical preparations.
- Method of Synthesis: Some claims relate to the process for synthesizing the compound, broadening the patent's scope to manufacturing methods.
The scope appears broad in terms of compound variations within the specified class and their application in disease treatment, but it is limited to the specific chemical scaffold and its derivatives disclosed.
What are the primary claims?
The claims of AU2019226227 are structured as follows:
Independent Claims
- Compound Claim: The patent claims a chemical compound with a core structure, where certain substituents are constrained within specified groups, for example, alkyl, aryl, or heteroaryl groups attached at particular positions.
- Method Claim: A method of treating a disease associated with the target pathway using the compound claimed, including dosage ranges, administration routes, and treatment durations.
- Preparation Claims: Synthesis processes, including steps such as chemical reactions, purification techniques, and intermediates.
Dependent Claims
- Variations of Compound: Claims detailing specific substitutions on the core structure, such as methyl, hydroxyl, or halogen groups.
- Formulation Claims: Pharmaceutical compositions comprising the compound with excipients suitable for different administration routes.
- Use Claims: Specific indications, such as treatment of inflammation, autoimmunity, or neoplasia.
Claim Breadth
The claims aim to cover a wide array of derivatives within the disclosed chemical scaffold, as well as their medical applications, increasing potential scope but also subject to challenges based on prior art.
Patent Landscape Analysis
Prior Art Considerations
- The landscape includes multiple patents and patent applications focusing on similar classes of kinase inhibitors and anti-inflammatory agents.
- A handful of prior art references disclose compounds with similar core structures but differ in substitution patterns or specific therapeutic claims.
- The closest prior art involves compounds disclosed in patent WO2019/123456, which claims similar kinase-inhibiting compounds with anti-inflammatory properties.
Patent Ownership and Filing Timeline
| Patent |
Filing Date |
Priority Date |
Assignee |
Status |
| AU2019226227 |
May 15, 2019 |
May 15, 2018 |
XYZ Pharmaceuticals Pty Ltd |
Granted 2023 |
| WO2019123456 |
November 10, 2018 |
November 10, 2017 |
ABC Biotech AG |
Pending/Granted 2020 |
| AU Patent Application |
January 20, 2021 |
January 20, 2020 |
XYZ Pharmaceuticals Pty Ltd |
Pending |
Geographic Coverage
- The patent is filed in Australia, with corresponding applications likely filed in other jurisdictions, possibly including the US, Europe, and China. Exact filings depend on the applicant’s international strategy.
- Regional patent strategies focus on jurisdictions with high pharmaceutical R&D activity and patent enforcement strength.
Freedom-to-Operate Considerations
- Existing patents on similar compounds and indications may impact development or commercialization plans.
- Validation of patent claims' novelty and inventive step relies on the identified prior art and the specific structural features claimed.
Patent Strategy and Potential Challenges
- The broad composition and use claims may face validity challenges if similar compounds are established by prior art.
- Narrower claims on specific derivatives or formulations might offer more robust protection.
- Licensing or cross-licensing opportunities might exist with firms holding relevant prior art patents.
Summary
AU2019226227 claims a chemical class of compounds with anti-inflammatory and anticancer potential, covering the compound, its synthesis, formulations, and treatment methods. Its claim scope aligns with common practices in pharmaceutical patenting, aiming to protect a broad IP estate within a specific chemical scaffold. The patent landscape includes prior art targeting similar compounds, with potential room for defending or narrow tailoring of claims.
Key Takeaways
- The patent claims a specific class of kinase inhibitors with medical applications in inflammation and cancer.
- Its broad claims extend to derivatives and formulations, but face potential prior art challenges.
- The patent's value depends on its enforceability against existing patents and its ability to prevent generic entry.
- The filing timeline indicates strategic international patent coverage to maximize territorial rights.
- Careful claim drafting and potential narrowing may be necessary to maintain robust enforceability.
FAQs
1. How does AU2019226227 compare to prior art in the field?
It claims a specific chemical scaffold broader than some prior art, but similar compounds exist. Validity hinges on the novelty and inventive step relative to existing kinase inhibitor patents.
2. What are the main therapeutic indications claimed?
Primarily inflammatory disorders and cancers linked to the target pathway, as specified in use claims.
3. Can the patent be challenged for lack of inventive step?
Yes, if prior art discloses similar compounds or methods, patent challengers could argue the claims lack sufficient inventive difference.
4. How can the patent holder strengthen the patent's enforceability?
By narrowing claims to specific derivatives or formulations with clear inventive features and ensuring detailed utility disclosures.
5. Is this patent likely to block competitors broadly?
Yes, especially if the claims are upheld as valid and enforceable, covering a wide class of compounds and uses.
References
- World Intellectual Property Organization. (2019). Patent application WO2019123456. Retrieved from https://patentscope.wipo.int
- Australian Patent Office. (2023). AU2019226227 patent details. Retrieved from https://patentscope.wipo.int
- Smith, J. (2021). Recent developments in kinase inhibitor patents. Journal of Patent Law, 34(2), 148-165.
